Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92 % of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.
Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment / P. Vercellini, N. Vendola, A. Colombo, C. Passadore, L. Trespidi, P. G. Crosignani. - In: GYNECOLOGIC AND OBSTETRIC INVESTIGATION. - ISSN 0378-7346. - 34:2(1992), pp. 102-104.
Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment
P. Vercellini;L. Trespidi;P. G. Crosignani
1992
Abstract
Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92 % of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.